Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene entry, "LysM, putative peptidoglycan-binding, domain containing 4 pseudogene" (ENSG00000251300/LOC100287014), is classified as a human pseudogene and does not encode a functional protein. The LysM domain is a widely conserved carbohydrate-binding module present in thousands of proteins across prokaryotes and eukaryotes, primarily associated with binding to peptidoglycan and chitin and involved in functions like cell wall recognition, symbiosis, and innate immunity in other species[2][4]. In bacteria and some eukaryotes, LysM domains can mediate binding to polysaccharides or function as part of enzymes involved in cell wall metabolism[1][2][4]. However, in this pseudogene, there is no evidence of expression, function, or therapeutic relevance in humans. Therefore, it does not meet criteria for consideration as a molecular target, therapeutic receptor, or biomarker[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LysM, putative peptidoglycan-binding, domain containing 4 pseudogene.